GlassScriptPhysician profile
Shirley D Ocloo
NPI 1366448342
$4,059.59
in general payments reported to CMS, 2019-2025
30 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $130 · 2021: $501 · 2022: $683 · 2023: $982 · 2024: $669 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $548.70 | 2021-2025 | Dovato, Apretude, Rukobia |
| Glaxosmithkline, LLC. | $473.44 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Abbvie INC. | $448.68 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $402.01 | 2019-2022 | |
| Novo Nordisk INC | $379.53 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $325.27 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $210.78 | 2021-2025 | Vaxneuvance, Capvaxive, Enflonsia |
| Pfizer INC. | $177.69 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $161.67 | 2022-2023 | Quviviq |
| Gilead Sciences, INC. | $153.62 | 2022-2025 | |
| Amgen INC. | $128.92 | 2019-2021 | |
| Lilly USA, LLC | $123.07 | 2019-2025 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $85.06 | 2021-2025 | |
| Exact Sciences Corporation | $80.47 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $51.74 | 2024 | Freestyle Libre 3 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $47.85 | 2020-2023 | Doc Band |
| Janssen Biotech, INC. | $37.27 | 2022-2023 | Symtuza |
| Sanofi-Aventis U.S. LLC | $34.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.12 | 2022 | |
| Vanda Pharmaceuticals INC. | $21.69 | 2024 | Fanapt |
| Ironshore Pharmaceuticals INC. | $19.10 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.56 | 2020 | |
| Tris Pharma INC | $17.17 | 2019 | |
| Edwards Lifesciences Corporation | $16.30 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Valeritas, INC. | $15.94 | 2019 | |
| Sobi, INC | $13.09 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.61 | 2021 | |
| Shire North American Group INC | $12.24 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $10.99 | 2022 | |
| Sanofi Pasteur INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shirley Ocloo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.